作者：
Richard,LeBlanc [1]
;
Hira,Mian [2]
;
Donna,Reece [3]
;
Jiandong,Su [4]
;
Esther,Masih-Khan [4]
;
Michael,Chu [3]
;
Victor,Jimenez-Zepeda [4]
;
Michael,Sebag [5]
;
Kevin,Song [6]
;
Martha,Louzada [7]
;
Rami,Kotb [8]
;
Alissa,Visram [9]
;
Darrell,White [10]
;
Julie,Stakiw [11]
;
Antony,Reiman [12]
;
Muhammad,Aslam [13]
;
Debra,Bergstrom [14]
;
Rayan,Kaedbey [15]
;
Engin,Gul [16]
;
Christopher,Venner [17]
作者单位：
Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada.
[1]
Juravinski Cancer Centre (Hamilton-CCO), Hamilton, Ontario, Canada.
[2]
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
[3]
Canadian Myeloma Research Group, Toronto, Ontario, Canada.
[4]
Cross Cancer Institute, Edmonton, Alberta, Canada.
[5]
Tom Baker Cancer Center, Department of Hematology, University of Calgary, Calgary, Alberta, Canada.
[6]
Division of Hematology, McGill University Health Centre, Montreal, Quebec, Canada.
[7]
The Leukemia/Bone Marrow Transplant Program of BC, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
[8]
London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada.
[9]
Cancer Care Manitoba, Winnipeg, Manitoba, Canada.
[10]
The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
[11]
Division of Hematology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.
[12]
Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
[13]
Saint John Regional Hospital, Saint John, New Brunswick, Canada.
[14]
Allan Blair Cancer Center, Regina, Saskatchewan, Canada.
[15]
Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada.
[16]
Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
[17]
BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada.
[18]
DOI
10.1111/ejh.14082
PMID
37574220
发布时间
2023-10-02
换一批
换一批
